BIOFRONTERA AGBIOFRONTERA AGBIOFRONTERA AG

BIOFRONTERA AG

No trades
See on Supercharts
Market capitalization
‪22.08 M‬EUR
‪−44.17 M‬EUR
‪25.74 M‬EUR
‪44.05 M‬
Beta (1Y)
0.32

About BIOFRONTERA AG

Headquarters
Leverkusen
Employees (FY)
110
Founded
1997
ISIN
DE0006046113
FIGI
BBG000BV2BQ3
Biofrontera AG engages in the research, development, and marketing of dermatological products. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of B8F is 0.334 EUR — it has decreased by 3.47% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on XETR exchange BIOFRONTERA AG stocks are traded under the ticker B8F.
BIOFRONTERA AG is going to release the next earnings report on Apr 25, 2024. Keep track of upcoming events with our Earnings Calendar.
B8F stock is 16.99% volatile and has beta coefficient of 0.32. Check out the list of the most volatile stocks — is BIOFRONTERA AG there?
B8F earnings for the last quarter are −0.47 EUR per share, whereas the estimation was −0.08 EUR resulting in a −479.42% surprise. The estimated earnings for the next quarter are −0.23 EUR per share. See more details about BIOFRONTERA AG earnings.
BIOFRONTERA AG revenue for the last quarter amounts to ‪5.38 M‬ EUR despite the estimated figure of ‪6.81 M‬ EUR. In the next quarter revenue is expected to reach ‪9.57 M‬ EUR.
Yes, you can track BIOFRONTERA AG financials in yearly and quarterly reports right on TradingView.
B8F stock has risen by 3.73% compared to the previous week, the month change is a 1.76% fall, over the last year BIOFRONTERA AG has showed a 73.91% decrease.
Today BIOFRONTERA AG has the market capitalization of ‪22.08 M‬, it has increased by 1.76% over the last week.
No, B8F doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, B8F shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOFRONTERA AG stock right from TradingView charts — choose your broker and connect to your account.
B8F reached its all-time high on Feb 7, 2007 with the price of 13.102 EUR, and its all-time low was 0.282 EUR and was reached on Apr 19, 2024.
See other stocks reaching their highest and lowest prices.
As of Apr 24, 2024, the company has 110.00 employees. See our rating of the largest employees — is BIOFRONTERA AG on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOFRONTERA AG technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOFRONTERA AG stock shows the sell signal. See more of BIOFRONTERA AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.